FDA panel recommends altered COVID-19 vaccines to target omicron subvariants

In a 19-2 vote, FDA advisers recommended vaccine-makers to focus on updated, omicron-containing vaccines after a daylong meeting June 28.

The 21 voting members on the Vaccines and Related Biological Products Advisory Committee debated the question, "Does the committee recommend inclusion of a SARS-CoV-2 omicron component for COVID-19 booster vaccines in the United States?"